Superworth

Mineralys Therapeutics free cash flow MLYS

Cash from operations less capital spending, by quarter and over the last twelve months, from 2023.

Last 12 months, to Dec 31, 2025
−$142.4M
Latest quarter, Q4 FY25
−$37.9M
Fiscal year 2025
−$142.4M

Mineralys Therapeutics' free cash flow was −$142.4M over the twelve months to Dec 31, 2025.

In its latest quarter, Q4 FY25, it was −$37.9M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$142.4Mn/a
FY2024−$166.4Mn/a
FY2023−$81.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY25−$37.9Mn/a−$142.4M
Q3 FY25−$28.9Mn/a−$171.4M
Q2 FY25−$30.2Mn/a−$192.7M
Q1 FY25−$45.5Mn/a−$192.7M
Q4 FY24−$66.8Mn/a−$166.4M
Q3 FY24−$50.2Mn/a−$128.5M
Q2 FY24−$30.1Mn/a−$97.4M
Q1 FY24−$19.2Mn/a−$87.6M
Q4 FY23−$29Mn/a−$81.2M
Q3 FY23−$19Mn/an/a
Q2 FY23−$20.4Mn/an/a
Q1 FY23−$12.8Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Mineralys Therapeutics' size, closest first, today.

CompanyFree cash flow yield
MLYSMineralys Therapeuticsn/m
ANIPANI Pharmaceuticals10.4%
PAHCPhibro Animal Health0.6%
HRMYHarmony Biosciencesn/m
PBHPrestige Consumer Healthcare10.4%
ANABAnaptysbion/m
PCRXPacira BioSciences12.4%
OMEROmeros−5.7%
NRIXNurix Therapeutics13.4%
AMPHAmphastar Pharmaceuticals14.3%
OGNOrganon15.7%
Peer median11.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Mineralys Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.